Feraccru Evrópusambandið - íslenska - EMA (European Medicines Agency)

feraccru

norgine b.v. - járn maltól - blóðleysi, járnskortur - sýklalyf - feraccru er ætlað í fullorðnir fyrir meðferð járn skort.

Abstral Tungurótartafla 800 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

abstral tungurótartafla 800 míkróg

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 800 míkróg

Abstral Tungurótartafla 600 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

abstral tungurótartafla 600 míkróg

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 600 míkróg

Abstral Tungurótartafla 400 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

abstral tungurótartafla 400 míkróg

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 400 míkróg

Abstral Tungurótartafla 300 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

abstral tungurótartafla 300 míkróg

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 300 míkróg

Abstral Tungurótartafla 200 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

abstral tungurótartafla 200 míkróg

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 200 míkróg

Abstral Tungurótartafla 100 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

abstral tungurótartafla 100 míkróg

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 100 míkróg

Taxespira (previously Docetaxel Hospira UK Limited ) Evrópusambandið - íslenska - EMA (European Medicines Agency)

taxespira (previously docetaxel hospira uk limited )

hospira uk limited - dócetaxel þríhýdrat - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - Æxlishemjandi lyf - brjóst cancertaxespira ásamt doxórúbicíns og cýklófosfamíði er ætlað til viðbótar meðferð sjúklinga með:nýtilegt hnút-jákvæð brjóstakrabbamein;nýtilegt hnút-neikvæð brjóstakrabbamein. fyrir sjúklinga með nýtilegt hnút-neikvæð brjóstakrabbamein, viðbótar meðferð ætti að vera bundin við sjúklinga rétt til að fá lyfjameðferð samkvæmt á alþjóðavettvangi komið skilyrði fyrir aðal meðferð snemma brjóstakrabbamein. taxespira ásamt doxórúbicíns er ætlað fyrir sjúklinga með staðnum háþróaður eða brjóstakrabbamein sem hafa ekki áður fengið frumudrepandi meðferð fyrir þessu ástandi. taxespira sér er ætlað fyrir sjúklinga með staðnum háþróaður eða brjóstakrabbamein eftir bilun frumudrepandi meðferð. fyrri krabbameinslyfjameðferð ætti að hafa innihaldið anthracycline eða alkýlerandi efni. taxespira ásamt trastuzumab er ætlað fyrir meðferð sjúklinga með brjóstakrabbamein sem æxli yfir tjá her2 og sem áður hefur ekki fengið lyfjameðferð fyrir sjúklingum sjúkdómur. taxespira ásamt capecitabine er ætlað fyrir sjúklinga með staðnum háþróaður eða brjóstakrabbamein eftir bilun frumudrepandi lyfjameðferð. fyrri meðferð ætti að hafa innihaldið anthracyclin. ekki lítinn klefa lungnakrabbamein taxespira fram fyrir sjúklinga með staðnum háþróaður eða sjúklingum ekki lítið klefi lungnakrabbamein eftir bilun af áður en lyfjameðferð. taxespira ásamt cisplatíni er ætlað fyrir sjúklinga með unresectable, á staðnum háþróaður eða sjúklingum ekki lítið klefi lungnakrabba, í sjúklingar sem hafa ekki áður fengið lyfjameðferð í þessu ástandi. krabbamein í blöðruhálskirtli taxespira ásamt prednisone eða prednisólóni er ætlað fyrir sjúklinga með hormón svarar sjúklingum krabbamein í blöðruhálskirtli. krabbamein í maga taxespira ásamt cisplatíni og 5-fluorouracil er ætlað fyrir sjúklinga með sjúklingum með krabbamein í maga, þar á meðal krabbamein í maga junction, sem ekki hafa fengið áður en lyfjameðferð fyrir sjúklingum sjúkdómur. höfðinu og hálsinn krabbamein taxespira ásamt cisplatíni og 5-fluorouracil er ætlað til að framkalla meðferð sjúklinga með staðnum háþróaður æxli klefi krabbamein í höfðinu og hálsinn.

Tecentriq Evrópusambandið - íslenska - EMA (European Medicines Agency)

tecentriq

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - Æxlishemjandi lyf - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq eitt og sér er ætlað fyrir meðferð fullorðinn sjúklinga með staðnum háþróaður eða sjúklingum nsclc eftir áður en lyfjameðferð. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq eitt og sér er ætlað fyrir meðferð fullorðinn sjúklinga með staðnum háþróaður eða sjúklingum nsclc eftir áður en lyfjameðferð. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Keytruda Evrópusambandið - íslenska - EMA (European Medicines Agency)

keytruda

merck sharp & dohme b.v. - pembrolizumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; endometrial neoplasms - Æxlishemjandi lyf - melanomakeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with stage iib, iic, or with stage iii melanoma and lymph node involvement who have undergone complete resection. non small cell lung carcinoma (nsclc)keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 1% tps and who have received at least one prior chemotherapy regimen. sjúklingar með egfr eða t jákvæð æxli stökkbreytingar ætti líka að hafa fengið miða meðferð áður en þú færð keytruda. classical hodgkin lymphoma (chl)keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical hodgkin lymphoma who have failed autologous stem cell transplant (asct) or following at least two prior therapies when asct is not a treatment option. urothelial carcinomakeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express pd l1 with a combined positive score (cps) ≥ 10. head and neck squamous cell carcinoma (hnscc)keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 fu) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a cps ≥ 1. keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a ≥ 50% tps and progressing on or after platinum containing chemotherapy. renal cell carcinoma (rcc)keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) cancerscolorectal cancer (crc)keytruda as monotherapy is indicated for theadults with msi-h or dmmr colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (msi h) or mismatch repair deficient (dmmr) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  non-colorectal cancerskeytruda as monotherapy is indicated for the treatment of the following msi h or dmmr tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. oesophageal carcinomakeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or her-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express pd l1 with a cps ≥ 10. triple negative breast cancer (tnbc)keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express pd l1 with a cps ≥ 10 and who have not received prior chemotherapy for metastatic disease. endometrial carcinoma (ec)keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. cervical cancerkeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd l1 with a cps ≥ 1. gastric or gastro-oesophageal junction (gej) adenocarcinomakeytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps ≥ 1.